CDMO

Zent2U (www.zent2u.com) is a B2B platform of Zentiva established in 2019 to collaborate with customers on:

- Licensing-out dossiers developed by Zentiva

- Co-development opportunities by co-financing Zentiva's products in development

- CMO services by Zentiva in production ...

Value added Dasatinib (Teaser attached)  •  Dasatinib is a targeted therapy used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL)  •  Current available products on the market are not completely absorbed by those patients ...

Value added Abiraterone  •  Abiraterone is a medication used to treat prostate cancer  •  The recommended dose is 1,000 mg as a single daily dose that must not be taken with food.  •  Administering  with food results up to a 10-fold (AUC) and up to a 17-fo...

Innovative combination Finasteride + Tadalafil   • Both products individually are approved for BPH (Benign prostatic hyperplasia) in Europe.  • The most frequent adverse reactions are impotence and decreased libido in Finasteride. The benefit of Tadalafil is early onset of the...

A direct link to submit innovative project proposals

During the interview, Petra Valentova, Head of Prague Scientific at Zentiva answers the following questions: Is this the first time that you’ve visited the event? As a Head of Prague Scientific, would you tell us something more about it? What is your agenda looking like for the rest of CPHI?

During the interview Andrey Zaikin, Head of Sourcing and Growth Strategy at Zentiva answered the following questions: Andrey, you are Head of Sourcing and Growth strategy? Why are you coming to CPHI? How many partners are you meeting here? Do you expect any new business initiated here? What makes people attending the Zentiva booth?